Track topics on Twitter Track topics that are important to you
We list hundreds of Clinical Trials about "986165 diflunisal Healthy Participants" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.
We have published hundreds of 986165 diflunisal Healthy Participants news stories on BioPortfolio along with dozens of 986165 diflunisal Healthy Participants Clinical Trials and PubMed Articles about 986165 diflunisal Healthy Participants for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 986165 diflunisal Healthy Participants Companies in our database. You can also find out about relevant 986165 diflunisal Healthy Participants Drugs and Medications on this site too.
BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.
The purpose of this study is to assess the taste characteristics of BMS-986165 formulations, alone and mixed, in order to develop a pediatric oral form of BMS-986165.
The purpose of this study is to investigate BMS-986165 given as a tablet in healthy male participants.
An oral dose in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986165
The purpose of this study is to investigate the effects of experimental medication BMS-986165 in healthy male participants.
The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the systemic exposure of rosuvastatin in healthy participants.
This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Participants With Normal Kidney Function and Participants With Mild, Moderate, and Severe Kidney Damage and in Participants With End-Stage Kidney Disease on Dialysis
The purpose of this study is to investigate BMS-986165 in participants with different levels of kidney function.
Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.
The purpose of this study is to evaluate the effects of stomach acid suppression by rabeprazole and BMS-986165 on how fast and complete the drug is absorbed into the body of healthy participants.
The primary purpose of this study is to evaluate the effects of food and pH on the relative bioavailability (BA) of the tablet formulation of BMS-986165 in healthy volunteers
The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.
To compare the pharmacokinetic characteristics of BMS-986165 after a single-dose administration alone vs. in combination with fluvoxamine (CYP1A2 inhibitor)
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
The purpose of this study is to investigate effects of BMS-986165 on blood levels of methotrexate given as a single dose in healthy male patients.
The Study of Cytochrome P450 1A2 Induction by Ritonavir on the drug effects of BMS-986165 in Healthy Participants
Study of what the body does to drug BMS-986165 when it is taken together with pyrimethamine
This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.
The purpose of this study is to investigate the effect of BMS-986165 in combination with an oral contraceptive in healthy female patients.
The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.
The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).
The main purpose of this study is to characterize the long-term safety and efficacy of the drug BMS-986165 in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.
The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans. It will be run in 5 Parts. Part A will investigate single oral doses of drug. Part B will investigate giving the drug daily for 14 days. Part C will investigate daily dos...
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.